OPINION (Daily Mail) – An experimental vaccine may someday prevent colorectal cancer in people with a genetic condition that pus them at high risk, new research suggests. Lynch Syndrome is a genetic condition that affects about 1.17 million Americans who are 70 to 80 percent more at-risk for colorectal cancer than the rest of the population. They are also predisposed to develop other gastrointestinal cancers, and women with Lynch
Syndrome are at greater risk of uterine and ovarian cancers. Scientists at Weill Cornell Medicine developed a vaccine that destroyed the mutated cells made by Lynch DNA in mice. The mice that the researchers vaccinated and gave a common anti-inflammatory drug to lived up to 60 percent longer than unvaccinated animals, suggesting that, if the shot is developed for humans, it could protect people from lethal cancers. READ MORE
